Final answer:
The correct answer is that D2 antagonist/First generation antipsychotics are not referred to as Atypical antipsychotics, Second generation antipsychotics, or Newer antipsychotics. These terms describe the newer class of medications that have a different pharmacological profile and are preferred because they typically offer fewer side effects.
Step-by-step explanation:
The other names for D2 antagonist/First generation antipsychotics, also known as Conventional or Typical antipsychotics, do not include Atypical antipsychotics, Second generation antipsychotics, or Newer antipsychotics. These terms are actually used to refer to a different class of antipsychotic drugs that have a different pharmacological profile than the first generation antipsychotics. The first generation drugs are known to antagonize dopamine D2 receptors and were the standard treatment for conditions like schizophrenia and bipolar disorder before the development of newer agents.
The development of schizophrenia and related psychotic disorders has been linked to overactive dopamine neurotransmission. The phenothiazines, such as chlorpromazine, is a classic example of first generation antipsychotics that manage these symptoms by blocking dopamine receptors. On the other hand, newer agents, such as risperidone, which were introduced in the 1990s, belong to the second generation or atypical antipsychotics and have a broader spectrum of receptor antagonism, including serotonin type 2 receptors.
First generation antipsychotics are known to reduce psychotic symptoms, such as hallucinations and delusions, and have additional effects, including antiemetic and antihistaminic properties. Nevertheless, due to their dopamine receptor antagonism, these drugs can cause side effects similar to Parkinson's disease, a condition known for low levels of dopamine. In contrast, Newer antipsychotics often have a lower risk of these side effects and are hence preferred in many cases.